GlassScriptPhysician profile
Peter Manning Jordan
NPI 1235286626
$6,360.71
in general payments reported to CMS, 2019-2025
37 companies · $768 in 2025
The $768 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,551 · 2020: $341 · 2021: $457 · 2022: $1,020 · 2023: $1,200 · 2024: $1,024 · 2025: $768.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,992.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,992.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $872.81 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $694.80 | 2019-2025 | |
| Shockwave Medical, INC | $562.41 | 2021-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Abbott Laboratories | $545.11 | 2019-2025 | Optis, Pressurewire, Cardiomems |
| Abiomed | $349.08 | 2019-2025 | Impella |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $325.85 | 2019-2025 | Lifevest |
| Penumbra, INC. | $300.47 | 2019-2022 | |
| Pfizer INC. | $294.94 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $280.99 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $279.21 | 2019-2024 | Wainua, Brilinta, Farxiga |
| Janssen Pharmaceuticals, INC | $257.39 | 2019-2024 | Xarelto |
| Medtronic, INC. | $176.67 | 2021-2024 | Onyx Frontier, Telescope |
| Zoll Circulation INC | $146.56 | 2023 | Downstream Cartridge, Therox Ds2 Console, Catheter |
| Teleflex LLC | $116.66 | 2019-2025 | Twin-Pass |
| Sanofi-Aventis U.S. LLC | $110.86 | 2019-2023 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Jordan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.